45
Participants
Start Date
February 14, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2028
Atezolizumab plus Tiraglolumab
All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
RECRUITING
Hospital General de Ciudad Real, Ciudad Real
RECRUITING
Complejo Asistencial Universitario de León, León
RECRUITING
Hospital Arnau de Vilanova, Lleida
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
HU Puerta de Hierro Majadahonda, Majadahonda
RECRUITING
Hospital General Universitario de Toledo, Toledo
RECRUITING
Consorcio Hospital General Universitario de Valencia, Valencia
RECRUITING
Hospital Universitario y Politécnico la Fe de Valencia, Valencia
RECRUITING
Hospital Universitario Miguel Servet, Zaragoza
RECRUITING
Hospital Universitario Son Espases, Palma de Mallorca
RECRUITING
Institut Català d'Oncologia (ICO) Hospitalet, L'Hospitalet de Llobregat
RECRUITING
Hospital Sant Joan Despí, Martorell
RECRUITING
Consorcio Corporación Sanitaria Parc Taulí, Sabadell
RECRUITING
Hospital de la Santa Creu i Sant Pau, Barcelona
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
Hoffmann-La Roche
INDUSTRY
Grupo Espanol Multidisciplinario del Cancer Digestivo
OTHER